(light music)
- Hello, I'm Doctor John Warner,
President of the American
Heart Association.
As you know, the mission
of the AHA is building
healthier lives, free of
cardiovascular disease and stroke.
The way the AHA does
that is through science.
Each year, the highlight
of our scientific program
is our scientific sessions,
which this year will be
in Anaheim, California,
November 11th through 15th.
There will be seven
late-breaking clinical trial
sessions at this year's
scientific meeting,
and each will be focused
on the clinical problems
that many of us face every day as we care
for patients with cardiovascular disease.
Those include clinical trials
looking at caring for patients
who have undergone
coronary bypass grafting
and the dilemmas that
many of us face in caring
for patients who have
electrophysiology diagnoses.
There will be a big focus
on prevention in this year's
late-breaking clinical trials,
as many trials are providing
important information about
preventing the downstream
effects of cardiovascular
disease and stroke.
This will be an important
meeting in regards
to hypertension, as the
hypertension guidelines
will be released during this session,
and they'll be many programs
focused on the content
of the guidelines and
the evidence behind them
in the late-breaking
events in clinical trials,
which will inform the way we care
for patients with hypertension.
Precision medicine and
the impact of big data
in cardiovascular science
will be important themes
at this year's meeting, as well.
Eric Dishman, who
directs the NIH Precision
Medicine Program, will
give the Lewis A. Conner
Memorial Lecture, and
Professor Sir Rory Collins,
will give the Paul Dudley White Lecture,
focusing on the differences
between observational science
in clinical trials, and
their impact, good and bad,
on the way we care for patients.
One of the more popular
features of last year's meeting
in New Orleans, were the
Frontiers in Science summits.
These Frontiers in Science
summits bring together
investigators and thought leaders
from all around the world,
coalescing around different
ideas and specific interest
in the treatment of heart
and vascular disease.
In these Frontiers in Science summits,
investigators will have a
chance to exchange ideas
and view the very best
science in areas like
vascular disease, stem cells,
and thrombosis research.
All of us who attend, or have
attended, scientific sessions,
understand the value of the meeting,
both as early career investigators
and as our professional
development continues and we
learn from our colleagues.
This year's meeting will
provide the very best
cardiovascular science
from around the world.
We hope you'll join us in
Anaheim for a terrific meeting
and we look forward to seeing you there,
and the chance for you to
be a part of the mission
of the American Heart Association
and the science that we support.
(light music)
